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JTT-130 was developed as an intestine-speciﬁc MTP inhibitor designed to rapidly catabolize after ab-
sorption to avoid causing hepatotoxicity due to hepatic MTP inhibition. In previous reports, we have
demonstrated that JTT-130 suppresses dietary lipid absorption in the small intestine without inducing
hepatic steatosis. Thus, in this report, JTT-130 was administered to hyperlipidemic animals fed a Western
diet to investigate the effect of intestinal MTP inhibition on lipid metabolism and progression of
atherosclerosis.
JTT-130 potently lowered plasma non-high density lipoprotein-cholesterol, and elevated plasma high
density lipoprotein-cholesterol (HDL-C), indicating improvement in atherogenic index in hamsters. HDL
fractions obtained after two weeks treatment with JTT-130 signiﬁcantly increased the efﬂux of choles-
terol from macrophages, as an index parameter of HDL function. Furthermore, long-term treatment with
JTT-130 also improved the plasma lipid proﬁle without inducing hepatic steatosis in rabbits, resulting in
the suppression of atherosclerosis formation in aortas.
From these results, JTT-130 ameliorates lipid metabolism accompanied with the enhancement of the
anti-atherosclerotic function of HDL, and attenuates the progression of atherosclerosis in hyperlipidemic
animals. These ﬁndings indicate that intestinal MTP inhibition may be atherogenic in vivo and that JTT-
130 may be a useful compound for the treatment of dyslipidemia and a potential anti-atherogenic drug.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Coronary heart disease (CHD) continues to be a leading cause of
morbidity and mortality worldwide. Dyslipidemia is one of the
most important risk factors for CHD (1,2). A lot of evidence has
shown that the primary objective for the management of dyslipi-
demia is reducing plasma low density lipoprotein-cholesterol (LDL-
C). LDL-C is oxidized after being incorporated into the endothelial
cell, and induces to form a vulnerable atherosclerotic plaque with
macrophages. Atherosclerosis is a progressive and symptomless
disease that starts early in life, and causes cardiovascular disease.
Therefore, the management of dyslipidemia is essential forrmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).attenuating the progression of coronary atherosclerosis and ulti-
mately reducing the risk of CHD (3). HMG-CoA reductase inhibitors
known as statins are recommended as the ﬁrst-line of treatment for
patients who need pharmacological intervention for dyslipidemia.
However, a signiﬁcant proportion of high-risk patient do not ach-
ieve the optimal LDL levels recommended in current guidelines. In
addition, patients who maintain low levels of LDL-C by statin
treatment experience CHD events (4,5). Therefore, there is still a
need to develop novel LDL-C lowering drugs that act via other
mechanisms differing from HMG-CoA reductase inhibition.
Recently, non-high density lipoprotein-cholesterol (non-HDL-C)
levels as well as LDL levels has been reported as a strong predictor
of CHD risk, and recommended as a treatment target of therapy for
patients with elevated triglyceride (TG) (6e8).
On the other hand, HDL demonstrates a large number of anti-
atherosclerotic actions that are not reﬂected in HDL-C levels (9).nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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macrophages, which is a key step in reverse cholesterol transport.
Recently, the cholesterol efﬂux capacity has been reported as being
inversely associated with the incidence of CHD events, indepen-
dentlyof theHDL-C levels. Therefore,HDL function, rather thanHDL-
C levels, is more important for the prevention of CHD events (10).
Microsomal triglyceride transfer protein (MTP) has been known
to take part in the mobilization and secretion of triglyceride-rich
lipoprotein, such as chylomicrons in enterocytes and VLDL in he-
patocytes (11e13). Inhibition of hepatic MTP resulted in not only
reducing plasma lipids, but also in hepatic steatosis (14). Thus, we
developed JTT-130, a novel intestine-speciﬁc MTP inhibitor,
designed to rapidly hydrolyze to inactive metabolite immediately
after intestinal absorption. In our previous reports, we character-
ized the pharmacological proﬁle of JTT-130 as an intestine-speciﬁc
MTP inhibitor (15), and showed that JTT-130 may be useful in the
prevention and treatment of metabolic disorders, such as obesity
(16,17) and type II diabetes (18) in several animal models. However,
whether JTT-130 can ameliorate lipid metabolism and attenuate
atherosclerosis by only inhibiting lipid absorption remains to be
determined. In the present studies, we evaluated the effects of JTT-
130 on lipid metabolism and atherosclerosis using hyperlipidemic
animal models. In the ﬁrst part of the study, we examined the
pharmacological proﬁles of JTT-130 associated with lipid meta-
bolism including HDL-mediated cholesterol efﬂux in hamsters. In
the second part of the study, furthermore, the anti-atherosclerotic
effects of JTT-130 were investigated in rabbits.2. Materials and methods
2.1. Materials
JTT-130 was synthesized at Central Pharmaceutical Research
Institute, Japan Tobacco Inc. (Osaka, Japan). All other reagents used
in this study were obtained commercially.2.2. Animals and diets
Male 8-week-old Syrian hamsters and Japanese White rabbits
were purchased from Japan SLC, Inc. (Shizuoka, Japan) and
Kitayama Labes Co., Ltd. (Nagano, Japan), respectively. The animals
were maintained on CE-2 (CLEA Japan, Inc., Tokyo, Japan) or RC-4
(Oriental Yeast Co., Ltd., Tokyo, Japan) as standard laboratory
chow diets and water ad libitum. The animals were housed under
speciﬁc pathogen-free conditions in a room controlled for tem-
perature at 23 ± 3 C and 55 ± 15% humidity in 12-h lightedark
cycles (lights on from 8:00 to 20:00). Prior to the initiation of the
animal study, the outline animal study protocol had been approved
by the research institution after a review by the Institutional Ani-
mal Care and Use Committee of the Central Pharmaceutical
Research Institute, Japan Tobacco Inc. This animal study was con-
ducted in accordance with the Japanese Law for the Humane
Treatment and Management of Animals.2.3. Triglyceride transfer activities of rabbit MTP
Triglyceride (TG) transfer activities of MTP derived from the
livers of rabbits were assessed according to a method described
previously (15). MTP protein was partially puriﬁed from micro-
somes of rabbit livers (XenoTech, LLC, Lenexa, KS) using fast protein
liquid chromatography (Pharmacia Biotech, Uppsala, Sweden)
equipped with DEAE-sepharose columns.2.4. Administration of JTT-130 in hyperlipidemic hamsters fed a
high-fat and high-cholesterol diet
Male 9-week-old Syrian hamsters were acclimatized to a high-
fat and high-cholesterol (HF/HC-h, CE-2 containing 0.5% choles-
terol and 10% coconut oil) diet, which was limited to 7 g/day to
supply the same amount of fat and cholesterol to all animals. JTT-
130 was administered as a food admixture (limited to 7 g/day) at
a dose equivalent to 1, 3 and 10 mg/kg/day (0.0016, 0.0049 and
0.0164% (w/w), respectively) for 14 days. The normal group was fed
a normal chow diet (CE-2, 7 g/day). Blood samples were collected
from the orbital venous plexus under ether anesthesia after two
weeks of treatment with JTT-130.
2.5. TG absorption in rabbits fed a high-fat and high-cholesterol
diet
Male 9-week-old Japanese white rabbits were acclimatized to a
high-fat and high-cholesterol (HF/HC-r, RC-4 containing 0.3%
cholesterol and 3% peanut oil) diet, which was limited to 70 g/day
to supply the same amount of fat and cholesterol to all animals. JTT-
130 was administered as a food admixture (limited to 70 g/day) at a
dose equivalent to 1, 3 and 10mg/kg/day (0.003, 0.09 and 0.03% (w/
w), respectively). The normal group was fed a normal chow diet
(RC-4, 70 g/day). Blood samples were collected from the auricular
artery 6 h after feeding.
2.6. Administration of JTT-130 to rabbits fed an HF/HC-r diet
Male 9-week-old Japanesewhite rabbits were acclimatized to an
HF/HC-r diet, which was limited to 100 g/day to supply the same
amount of fat and cholesterol to all animals. JTT-130 was
administered as a food admixture (limited to 100 g/day) at a
dose equivalent to 3 and 10 mg/kg/day (0.00825e0.009 and
0.0275e0.03% (w/w), respectively) for 12 weeks. The normal group
was fed a normal chow diet (RC-4, 100 g/day). Blood samples were
collected from the auricular artery after 1, 2, 4, 8, and 12 weeks of
treatment with JTT-130.
2.7. Measurement of blood chemical parameters
Non-fasting plasma parameters, such as TG and total cholesterol
(TC), weremeasured using LiquiTech TGII and LiquiTech TCII (Roche
Diagnostics, Basel, Switzerland) and an automatic analyzer (Model
7170S, Hitachi, Ltd., Tokyo, Japan). To measure HDL-C, plasma
samples were mixed with the same amount of 15% polyethylene
glycol 6000, kept at room temperature for 10 min and centrifuged
at 10,000 g for 5 min. HDL-C obtained in the supernatant was
measured with LiquiTech TCII using an automatic analyzer. Non-
HDL-C was calculated by subtracting HDL-C from TC. Atherogenic
index was expressed as non-HDL-C/HDL-C (19e22). Plasma chylo-
micron (CM)-TG was measured according to a method described
previously (15).
2.8. Measurement of fecal free fatty acid and TC
Fecal free fatty acid content was assessed according to a method
described previously (17). JTT-130 was administered as a food
admixture (limited to 7 g/day) at a dose equivalent to 3 mg/kg/day
(0.0049% (w/w)). Feces of hamsters were collected from Day 1 to
Day 8 of JTT-130 treatment. The feces were dried, weighed and
powdered and fecal free fatty acids were extracted from 100 mg
of the powdered feces with chloroform/methanol (2:1, vol/vol).
An aliquot of the organic phase was dried and resuspended in
isopropyl alcohol. Extracted free fatty acids and TC were
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Chemical Industries, Ltd., Osaka, Japan) and LiquiTech TCII.2.9. HDL-mediated cholesterol efﬂux from THP-1 macrophages
THP-1 cells (American Type Culture Collection, Rockville, MD), a
human acute monocytic leukemia cell line, were maintained in
RPMI 1640 medium supplemented with 10% (v/v) heat inactivated
fetal bovine serum (FBS), 100 U/mL penicillin and 100 mg/mL
streptomycin at 37 C in 5% CO2. The cells were plated onto 24-mm
diameter plates at a density of 5  105 cells/well and treated with
100 ng/mL phorbol 12-myristate 13-acetate (PMA, SigmaeAldrich,
St. Louis, MO) for 7 days to facilitate differentiation into macro-
phages. The differentiated THP-1 macrophages were incubated
with RPMI 1640 medium containing 1 mCi/mL (37 kBq/mL) [1,
2-3H(N)]-cholesterol (PerkinElmer, Waltham, MA),100 ng/mL PMA,
5% (v/v) FBS and 1.5% (w/v) bovine serum albumin (BSA) for 24 h.
Macrophages were washed with RPMI 1640 medium and replaced
with RPMI 1640 medium containing 100 ng/mL PMA. HDL fractions
(10 mL/500 mL medium) obtained after two weeks treatment of JTT-
130 were added to medium in order to cause an efﬂux from mac-
rophages to HDL for 24 h [3H]-radioactivity was measured in cul-
ture media and the cells after a 24-h incubation. The cholesterol
efﬂux rate mediated by HDL was expressed as the ratio of [3H]-
radioactivity released from macrophages into the medium.2.10. Analysis of the area of atherosclerotic lesions
The aortas were also removed from the animals under pento-
barbital anesthesia. Aortas were stained for lipids by immersion in
0.5% Sudan III staining solution (35% ethanol, 50% acetone). An
evaluation of atherosclerotic lesions was subsequently performed
by dividing the area into three regions; the aortic arch, thoracic
aorta and abdominal aorta. The aortic arch was deﬁned as the re-
gion from the origin of the aorta to the distal side 5 mm from the
left subclavian artery, the thoracic aorta was deﬁned as the region
from the end of the aortic arch to the diaphragm, and the abdom-
inal aorta was deﬁned as the region after the diaphragm. The
percent area of arteriosclerotic lesions (%) in evaluated regions was
calculated after photographing aorta specimens (intravascular
lumen) with a digital still camera and scoring the image area using
analytical software (Adobe Photoshop and MacSCOPE).2.11. Measurement of hepatic TG and TC content
After the treatment period of JTT-130, animals were sacriﬁced
under anesthesia and liver tissues were removed from the animals.
Livers were homogenized in chloroform/methanol (2:1, vol/vol). An
aliquot of the organic phase was collected, dried and resuspended
in isopropyl alcohol. Extracted triglycerides and cholesterol were
enzymatically determined using Triglyceride G-Test Wako (Wako
Pure Chemical Industries, Ltd., Osaka, Japan) or LiquiTech TGII, and
LiquiTech TCII.2.12. Histopathological analysis of liver tissues and aortas
The liver tissues and aortas were collected from the animals
after JTT-130 treatment and ﬁxed in 10% neutral buffered formalin.
Slide specimens were prepared for histopathological examination
by embedding in parafﬁn wax, sectioning and staining with he-
matoxylin and eosin (HE). All of the HE-stained sections were
examined microscopically.2.13. Statistical analysis for in vivo studies
Data are presented as the mean ± S.E. Statistical analyses were
performed as follows:
Differences between the Normal group and Control group, or
between the Control group and JTT-130 group, were tested using F
test, followed by Student's t test for equal variances or Welch's t-
test for unequal variances.
Differences between the Control group and JTT-130 groups were
tested using Bartlett's homogeneity of variance test, followed by
Dunnett's multiple comparison test for equal variances or Steel's
multiple comparison test for unequal variances.
Differences were considered signiﬁcant at p < 0.05. StatLight
(1998 (C), Yukms Corp.) was used for the statistical analysis.
3. Results
3.1. Effects of 2-week administration of JTT-130 on lipid metabolism
in hamsters fed an HF/HC-h diet
The effects of JTT-130 administered as a dietary admixture for 2
weeks on plasma lipid levels and hepatic lipid content were
investigated using hyperlipidemic hamsters fed an HF/HC-h diet.
This study was performed under conditions where the same
amount of diet was provided to supply the same amount of fat and
cholesterol. The actual mean dosages were calculated as 1.0, 3.1 and
10.6 mg/kg/day during the study period.
Table 1 shows the effect of two weeks of treatment with JTT-130
on lipid metabolism. Plasma CM-TG levels, an index parameter of
intestinal absorption, in JTT-130 treated groups decreased signiﬁ-
cantly at a dose of 3.1 mg/kg/day compared with the control group.
To conﬁrm the inhibitory effects of JTT-130 on lipid absorption,
feces were collected from Day 1 to Day 8 after starting JTT-130
treatment and free fatty acid and cholesterol content in the feces
were measured in a separate study. Free fatty acid and cholesterol
content in the feces of animals in the JTT-130 group increased
compared with that in the control group, suggesting that JTT-130
excreted lipids out of the body as a result of inhibition of lipid ab-
sorption (Table 2).
JTT-130 reduced plasma TC and TG in a dose-dependent manner
(Table 1), as previously reported (15). In addition, JTT-130 elevated
plasma HDL-C at doses of 1.0 mg/kg/day and higher and reduced
plasma non-HDL-C at doses of 3.1 mg/kg/day and higher, resulting
in signiﬁcant improvements in atherogenic index (non-HDL-C/
HDL-C) (Table 1).
Following the increase in HDL-C after two weeks of treatment
with JTT-130, HDL-mediated cholesterol efﬂux from macrophages,
a metric of HDL function, was evaluated using differentiated THP-1
macrophages and HDL fractions obtained after JTT-130 treatment.
An increase in [3H]-radioactivity in the medium was observed in
HDL from the JTT-130 group compared with that from the control
group, indicating that cholesterol efﬂux rate in the JTT-130 group
was signiﬁcantly higher than that in the control group (Table 3).
Hepatic lipid content was also evaluated after two weeks treat-
ment with JTT-130. Hepatic TG and TC content in the control group
increased signiﬁcantly with HF/HC-h diet feeding. Compared with
the control group, hepatic TG and TC content in the JTT-130 group
decreased signiﬁcantly at doses of 3.1mg/kg/dayandhigher (Table 1).
3.2. Effects of 12-week administration of JTT-130 on lipid
metabolism in rabbits fed an HF/HC-r diet
3.2.1. In vitro TG transfer activity with rabbit MTP
The effects of JTT-130 on atherosclerosis were also elucidated in
rabbits fed an HF/HC-r diet. Prior to the in vivo study, TG transfer
Table 1
Effects of JTT-130 on plasma lipid parameters and hepatic lipid contents in hamsters fed an HF/HC-h diet.
Parameters Normal
(Normal diet)
Control
(HF/HC-h diet)
JTT-130 (mg/kg/day)
1.0
(HF/HC-h diet)
3.1
(HF/HC-h diet)
10.6
(HF/HC-h diet)
Plasma CM-TG (mg/dL) 25.3 ± 5.2 67.6 ± 11.0y 45.1 ± 7.1 34.6 ± 8.0* 7.5 ± 2.4**
Plasma TG (mg/dL) 120.1 ± 15.7 391.6 ± 36.5yy 364.6 ± 17.7 285.3 ± 35.5* 248.0 ± 25.7**
Plasma TC (mg/dL) 219.7 ± 4.7 779.5 ± 21.2yy 796.6 ± 29.7 628.6 ± 25.2** 400.0 ± 15.4**
Plasma HDL-C (mg/dL) 94.0 ± 3.2 119.8 ± 4.5yy 137.6 ± 3.7** 143.4 ± 3.4** 135.3 ± 3.8*
Plasma non-HDL-C (mg/dL) 125.7 ± 2.8 659.7 ± 22.5yy 659.0 ± 30.0 485.1 ± 24.0** 264.7 ± 12.6**
Atherogenic index (non-HDL-C/HDL-C) 1.34 ± 0.04 5.59 ± 0.31yy 4.82 ± 0.26 3.39 ± 0.17** 1.95 ± 0.07**
Hepatic TG content (mg/g tissue) 7.7 ± 0.2 12.2 ± 0.2yy 12.3 ± 0.3 10.8 ± 0.3** 7.8 ± 0.3**
Hepatic TC content (mg/g tissue) 23.8 ± 1.4 59.5 ± 1.3yy 59.5 ± 1.7 45.6 ± 1.6** 23.8 ± 1.5**
Plasma lipid parameters and hepatic lipid contents were measured on Day 15 under non-fasting conditions. Hepatic TG and TC were extracted on Day 15 under non-fasting
conditions as described in the Material and Methods section.
Each value represents the mean ± S.E. (n ¼ 10, only Normal group: n ¼ 6).
**: p < 0.01,*: p < 0.05 versus Control group (Dunnett's test or Steel's test).
yy: p < 0.01,y: p < 0.05 versus Normal group (t-test).
Table 2
Fecal excretion of free fatty acid and cholesterol in hamsters fed an HF/HC-h diet.
Parameters Normal
(Normal diet)
Control
(HF/HC-h diet)
JTT-130 3.1 mg/kg/day
(HF/HC-h diet)
Fecal free fatty
acid (mg/g)
0.37 ± 0.06 1.22 ± 0.04yy 2.36 ± 0.13**
Fecal TC (mg/g) 3.07 ± 0.63 7.43 ± 0.33yy 10.19 ± 0.99*
Feces were collected for 7 days from Day 1 to Day 8 of treatment with JTT-130 in
hamsters fed an HF/HC-h diet.
Fecal free fatty acid and TCweremeasured as described in theMaterial andMethods
section.
Mean ± S.E. (n ¼ 6, only Normal group: n ¼ 3).
**: p < 0.01,*: p < 0.05 versus Control group (t-test).
yy: p < 0.01 versus Normal group (t-test).
Table 3
HDL-mediated cholesterol efﬂux from THP-1 macrophages.
Parameters Control
(HF/HC-h diet)
JTT-130 3.1 mg/kg/day
(HF/HC-h diet)
Plasma HDL-C (mg/dL) 119.2 ± 4.4 137.5 ± 4.4**
Efﬂux rate (%) 18.85 ± 0.40 20.74 ± 0.64*
HDL-mediated cholesterol efﬂux was evaluated in differentiated THP-1 macro-
phages.
Immediately after blood sampling on Day 15 after the start of JTT-130 administra-
tion, additional feeding of JTT-130 food admixture was started.
HDL fractions were obtained 4 h after feeding, and were added to THP-1 macro-
phages to cause an efﬂux of [3H]-labeled cholesterol from macrophages.
Mean ± S.E. (n ¼ 10).
*: p < 0.05 versus Control group (t-test).
* *
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Fig. 1. Effects of JTT-130 on postprandial TG in rabbits fed an HF/HC-r diet. JTT-130
was administered orally to rabbits as a food admixture (70 g). The control group was
fed HF/HC-r diet (70 g) without JTT-130, and the normal group was fed a basal diet
(ND, 70 g). Blood samples were collected to measure plasma TG 6 h after start of
feeding. Each value represents the mean ± S.E. (n ¼ 6, only Normal group: n ¼ 3).
*: p < 0.05 versus Control group (Steel's test).
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in vitro. JTT-130 potently inhibited TG transfer by hepatic MTP
derived from rabbits in a concentration-dependent manner and the
IC50 value for the TG transfer was 0.33 nM. As previously reported,
there were no species differences in the potency of the inhibition,
the IC50 values for these species being comparable with values for
hamsters (0.51 nM) and humans (0.25 nM) (15). Comparatively, the
major metabolite of JTT-130 showed no inhibitory effects on he-
patic MTP from rabbits up to 30,000 nM, similar to observations in
hamsters and humans.
3.2.2. Plasma postprandial TG in rabbits fed an HF/HC-r diet
The effects of JTT-130 on postprandial TG were evaluated to ﬁnd
an adequate dose for the long-term study of JTT-130 in hyper-
lipidemic rabbits fed an HF/HC-r diet. JTT-130 was administered as a
dietary admixture through restricted feeding (70 g/day). The actual
mean dosages were calculated as 0.3, 1.0, 3.0 and 10.5 mg/kg/day.
Since all animals ﬁnished eatingwithin 6 h after the feeding, plasmaTG levels were measured to evaluate the effects of JTT-130 on post-
prandial TG. JTT-130 potently suppressed the elevation of plasma TG
at 6 h after feeding at doses of 3.0 mg/kg/day and higher (Fig. 1).
3.2.3. Plasma lipid levels in rabbits fed an HF/HC-r diet
The effects of administration of JTT-130 as a dietary admixture
for 12 weeks on plasma lipid levels and liver lipid content were
investigated using hyperlipidemic rabbits fed an HF/HC-r diet
(Fig. 2). The actual mean dosages were calculated as 3.2 and
10.9 mg/kg/day during the 12-week treatment period. After one
week treatment, JTT-130 lowered TC, which was otherwise elevat
ed by the HF/HC-r diet, in comparison with the control group at
doses of 3.2 mg/kg and higher (Fig. 2-A). This TC lowering effect of
JTT-130 persisted throughout the study period. Plasma HDL-C ele-
vations were more pronounced in the 3.2 mg/kg and 10.9 mg/kg
groups compared with the control group after two weeks of
administration and the values were still slightly higher than that in
the control group after 12-week treatment (Fig. 2-B). Non-HDL-C
(difference between TC and HDL-C) showed the similar decrease
with TC (Fig. 2-C) and, as a result, the atherogenic index (non-HDL-
C/HDL-C) in the JTT-130 groups decreased in a dose dependent
manner compared with that in the control group (Fig. 2-D).
3.2.4. Body weight and body weight gain in rabbits fed an HF/HC-r
diet
After administration of JTT-130 for 12 weeks, body weight in the
JTT-130 treated groups decreased signiﬁcantly at dose of 10.9 mg/
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Fig. 2. Effects of JTT-130 on plasma lipid parameters in rabbits fed an HF/HC-r diet. JTT-130 was administered orally to rabbits as a food admixture (100 g/day). The control group
was fed HF/HC-r diet (100 g/day) without JTT-130, and the normal group was fed a basal diet (ND, 100 g/day). After 1, 2, 4, 8 and 12 weeks treatment with JTT130, blood samples
were collected to measure plasma lipid parameters 6 h after start of feeding. Plasma TC (A) and HDL-C (B) were measured. Non-HDL-C (C) and atherogenic index (D) were calculated
as described in the Materials and Methods section. Each value represents the mean ± S.E. (n ¼ 10, only Normal group: n ¼ 6). yy: p < 0.01, y: p < 0.05 versus Normal group (t-test),
**: p < 0.01, *: p < 0.05 versus Control group (Dunnett's test or Steel's test).
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control group and JTT-130 treated groups were observed at dose of
10.9 mg/kg/day (Table 4).3.2.5. Hepatic lipid accumulation in rabbits fed an HF/HC-r diet
Hepatic lipid content was examined to evaluate the effects of
JTT-130 on hepatic steatosis induced by an HF/HC-r diet after 12
weeks of JTT-130 administration (Fig. 3). Hepatic cholesterol con-
tent in the control group increased signiﬁcantly with the HF/HC-r
diet compared with that of the normal diet group. Hepatic
cholesterol content in the JTT-130 groups decreased signiﬁcantly at
doses of 3.2 mg/kg/day and higher compared with that of the
control group (Fig. 3-A). Hepatic TG content could not be deter-
mined since the extracts turnedwhite, whichwas likely due to high
cholesterol content in the liver. Therefore, histological analyses ofTable 4
Effects of JTT-130 on body weight and body weight gain in rabbits fed an HF/HC-r
diet.
Parameters Normal
(Normal diet)
Control
(HF/HC-r diet)
JTT-130 (mg/kg/day)
3.2
(HF/HC-r diet)
10.9
(HF/HC-r diet)
Body weight (g) 3042.0 ± 48.9 3143.7 ± 37.0 3122.1 ± 49.7 2997.1 ± 44.2*
Body weight
gain (g)
1057.3 ± 35.9 1196.3 ± 29.9y 1176.0 ± 44.5 1065.9 ± 26.6*
Mean ± S.E. (n ¼ 11e12, only Normal group n ¼ 6).
*: p < 0.05 versus Control group (Dunnett's test).
y: p < 0.05 versus Normal group (t-test).liver sections stained with hematoxylin and eosin were performed
to evaluate the effects of JTT-130 on hepatic steatosis induced by an
HF/HC-r diet. Representative samples are shown in Fig. 3-B.
Extensive lipid droplets were seen in the hepatocytes of control
rabbits fed an HF/HC-r diet compared with that of normal rabbits.
Conversely, lipid droplets were rarely observed in liver sections
from JTT-130-treated rabbit.3.2.6. Atherosclerosis in the aorta in rabbits fed an HF/HC-r diet
The effects of JTT-130 on the onset and progress of atheroscle-
rosis in the aorta were evaluated by measuring the percent area of
atherogenic lesions. Lipid deposits due to long-term consumption
of an HF/HC-r diet were found in the aortas of animals in the control
group, and these deposits were most prominent in the aortic arch
(Fig. 4-A). JTT-130 potently decreased the percent area of athero-
sclerotic lesions and showed clear anti-atherosclerotic effects.
Signiﬁcant anti-atherosclerotic effects were observed at a dose of
10.9 mg/kg in all three parts of the aortas (Fig. 4-B).
Histopathological analyses of aortas were performed after 12
weeks of JTT-130 administration at a dose equivalent to 10 mg/
kg/day in a separate study and representative samples are shown
in Fig. 5. In the control group, thickening in the arterial wall
accompanied by aggregation of the foamy cells, increased
collagen ﬁbers, deposition of lipid droplet and edema in the
endothelium or subendothelial layer was observed (Fig. 5-A).
These ﬁndings were prominent in the root of the aorta when
compared to the peripheral-arterial wall. On the other hand,
these ﬁndings were ameliorated or disappeared in the JTT-130
treated animals (Fig. 5-B).
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Fig. 4. Effects of JTT-130 on atherosclerotic lesions in rabbits fed an HF/HC-r diet.
Aortas were stained for lipids by immersion in 0.5% Sudan III and macroscopic ﬁndings
were shown as typical examples (A). An evaluation of atherosclerotic lesions was
subsequently performed by dividing the area into three regions; the aortic arch,
thoracic aorta and abdominal aorta (B). Each value represents the mean ± S.E.
(n ¼ 11e12/group, only Normal group: n ¼ 6). **: p < 0.01, *: p < 0.05 versus Control
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normal diet.
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JTT-130 is a novel intestine-speciﬁc MTP inhibitor designed to
rapidly catabolize to inactive metabolites after absorption to avoid
the inhibition of hepatic MTP (15). The present study demonstrated
that JTT-130 treatment resulted in an improvement in lipid meta-
bolism and an attenuation of atherosclerosis without inducing
hepatic steatosis in hyperlipidemic animals fed an HF/HC diet. All of
the animal experiments were conducted under the condition of
restricted feeding, which is one of the methods to exclude the food
suppressive effect of JTT-130.
In the ﬁrst part of the study, the effects of JTT-130 on lipid
metabolism were investigated with hamsters fed an HF/HC-h diet.
JTT-130 lowered plasma CM-TG which is a surrogate marker of
intestinal TG absorption. Since increases in plasma intestinal lipo-
proteins due to overproduction and/or reduced catabolism induce
atherosclerosis, regulating CM secretion in the intestine may lead
to the prevention of atherosclerosis (23). JTT-130 also reduced
plasma TG, TC and non HDL-C, suggesting that JTT-130 continu-
ously inhibits intestinal MTP and suppresses lipid absorption. The
inhibition of lipid absorption by JTT-130 was also supported by the
increase in free fatty acid and cholesterol in feces collected fromJTT-130-treated hamsters. These ameliorations of lipid metabolism
with JTT-130 treatment were shown without accumulation of he-
patic TG and TC, as previously reported (15).
In addition, JTT-130 signiﬁcantly increased HDL-C levels at doses
of 1.0 mg/kg/day and higher, nevertheless of the decrease in TC
levels after JTT-130 treatment was observed at doses of 3.1 mg/kg/
day and higher. Interestingly, the increase in HDL-C levels became
apparent at a lower dose of JTT-130 than that of which observed the
decrease in TC. Plasma HDL-C levels have a strong inverse rela-
tionship to atherosclerotic cardiovascular disease (24). The central
anti-atherogenic activity of HDL is likely to be its ability to remove
cholesterol from macrophage foam cells. The efﬂux of cholesterol
from macrophage foam cells is thought to play a role in the stabi-
lization and regression of atherosclerotic plaques (25). We per-
formed a cholesterol efﬂux test using HDL-C fractions after JTT-130
treatment (3.1 mg/kg/day). JTT-130 signiﬁcantly increased the
efﬂux of [3H]-labeled cholesterol efﬂux from THP-1 macrophages
compared with that of control, suggesting that the elevated HDL-C
by JTT-130 treatment was accompanied with the increase in the
ability of HDL to accept cholesterol from macrophages. Recent
studies have reported that the cholesterol efﬂux capacity from
macrophages is inversely associated with carotid intima-media
thickness and the incidence of cardiovascular events, indepen-
dently of the HDL-C levels (10,26). Further investigations are
needed to explain the mechanism of HDL-C elevation and the in-
crease in cholesterol efﬂux from macrophages with JTT-130
A B
Fig. 5. Effects of JTT-130 on atherosclerosis formation in rabbits fed an HF/HC-r diet. Aortas were ﬁxed in 10% neutral buffered formalin. Slide specimens were prepared for
histopathological examination as described in the Materials and Methods section and stained with hematoxylin and eosin. Microscopic ﬁndings of the aortic root were shown as
typical examples of Control group (A) and JTT-130 10 mg/kg/day group (B). Bars ¼ 200 mm.
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MTP but not hepatic MTP, and the inhibition of secretion of ApoB
but not ApoA1 (15), which plays a crucial role in HDL production. As
the results of the increase in the HDL-C levels and the decrease in
non-HDL-C levels, JTT-130 showed improvement in atherogenic
index expressed as non-HDL-C/HDL-C. The amelioration of JTT-130
on lipid proﬁle in hamsters led us to investigate the effect of JTT-130
on atherosclerosis formation.
In the second part of the study, the effects of JTT-130 on the
onset and progress of atherosclerosis in the aorta were investigated
in rabbits fed an HF/HC-r diet to evaluate whether amelioration of
lipid metabolism with JTT-130 would lead to anti-atherosclerotic
effects. Rabbit models are one of the popular models which have
been used to evaluate the effects of lipid lowering drugs on
atherosclerosis (27,28).
In the in vitro study using MTP from rabbits, the potent inhibi-
tory effect of JTT-130 on TG transfer was conﬁrmed as shown by
MTPs from other species (15). The doses for the long-term study of
JTT-130 were set at a dose equivalent to 3.0 and 10 mg/kg/day,
which were the doses of JTT-130 that showed inhibitory effects on
TG absorption. Chronic treatment of JTT-130 potently reduced
plasma TC and non-HDL-C levels during the treatment period. JTT-
130 also reduced plasma LDL-C levels determined by density
gradient separation of plasma lipoprotein after a week of JTT-130
treatment in a separate study (Normal diet group; 3.9 ± 0.9 mg/
dL, HF/HC-r diet; Control group: 207.9 ± 15.8 mg/dL, JTT-130
3.0 mg/kg/day group: 140.9 ± 27.7 mg/dL, JTT-130 10.1 mg/kg/day
group: 137.3 ± 24.2 mg/dL). While no obvious elevations in HDL-C
were observed with JTT-130 treatment, which contrasted with re-
sults from hamsters, probably because cholesterol absorption was
potently suppressed by JTT-130 treatment, plasma HDL-C eleva-
tions were more pronounced at doses of 3.2 mg/kg and 10.9 mg/kg
compared with that in the control group after two weeks of
administration. The atherogenic index expressed as non-HDL-C/
HDL-C, dramatically improved with JTT-130 treatment in a dose-
dependent manner. In response to the atherogenic index, JTT-130
potently reduced lipid deposits in aortas after 12-weeks of JTT-
130 treatment. Atherosclerosis is a chronic inﬂammatory disease
characterized by accumulation of foamy cells in arterial wall
(29e31). Foamy cells in the arterial wall induce the development of
an early atherosclerosis (32). In this study, the aggregation of foamy
cells in the arterial wall, increased collagen ﬁbers, deposition of
lipid droplet in endothelium layer, which are existed in athero-
sclerotic plaque, were observed in rabbits fed an HF/HC-r diet.
These ﬁndings were ameliorated or disappeared after JTT-130
treatment, suggesting that JTT-130 suppressed formation of
atherosclerosis only through inhibiting lipid absorption in theintestine. This is the ﬁrst report that anti-atherogenic effects was
shown only through the intestinal MTP inhibition, since these re-
sults with JTT-130 treatment were observed without the accumu-
lation of fat and cholesterol in the liver, which is a sign of inhibition
of hepatic MTP.
Furthermore, body weight also decreased with JTT-130 treat-
ment in spite of the restricted feeding condition. This effect appears
to be attributed to the inhibition of lipid absorption in the intestine
with JTT-130 treatment. The reduction in energy intake through the
inhibition of lipid absorption in the intestine is a preferable
approach for the treatment of obesity. Therefore, targeting intes-
tinal lipid absorption may be beneﬁcial in regulating dyslipidemia,
atherosclerosis and obesity, all of which are risk factors associated
with CHD.
In conclusion, JTT-130, a novel intestine-speciﬁc MTP inhibitor,
ameliorates lipid metabolism accompanied with an increase in
functional HDL, and inhibits the formation of atherosclerosis in
hyperlipidemic animals without inducing hepatic steatosis. These
ﬁndings indicate that the inhibition of intestinal MTP may be
atherogenic in vivo and that JTT-130 may be a useful compound for
the treatment of dyslipidemia and a potential anti-atherosclerotic
drug.
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